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Objective: A regional cooperative data registry was organized for carotid endarterectomy (CEA), lower extremity bypass
(LEB), and infrarenal abdominal aortic aneurysm (AAA) repair (open and endovascular) procedures in Northern New
England to allow benchmarking among centers for quality assurance and improvement activities.
Methods: Since January 2003, 48 vascular surgeons from nine hospitals in Maine, New Hampshire, and Vermont (25 to
615 beds) have prospectively recorded patient, procedure, and in-hospital patient outcome data. Results plus 1-year
follow-up data analyzed at a central site are reported anonymously to each center at semiannual meetings where care
processes and regional benchmarks are discussed. Mortality and compliance with procedure entry were validated by
independent comparison with hospital administrative data. Initial improvement efforts focused on optimizing preoper-
ative medication usage.
Results: A total of 6143 operations were entered into the registry through December 2006. In-hospital stroke or death
after CEA was 1.0%, major amputation or death after LEB was 3.8%, and mortality was 2.9% after elective open and 0.4%
after endovascular repair. Variation in results between centers and surgeons provides opportunity for further quality
improvement. Any postoperative complication increased median length of stay by >3 days. Process improvement efforts
initiated in 2004 increased preoperative -blocker administration from 72% to 91%, antiplatelet agents from 73% to 83%,
and statins from 54% to 72% (all P < .001). Procedure volume and discharge status validation with administrative data
led to 99% of appropriate operations being reported to the registry. Mortality was accurately reported to the data registry
for all patients.
Conclusion: This validated regional data registry within a quality improvement initiative has been associated with
improved preoperative medication usage. It provides a potential vehicle for future public and pay-for-performance
reporting and has the potential to improve patient outcomes. It has been sustained for>4 years and is a model that could
be adopted by other regions. ( J Vasc Surg 2007;46:1093-102.)In his 1994 Presidential Address to the Society for
Vascular Surgery, Dr Norman Hertzer urged vascular sur-
geons to track their outcomes, concluding that “results
mean everything.”1 He specifically encouraged a prospec-
tive audit of three index procedures: carotid endarterec-
tomy (CEA), lower extremity bypass, and abdominal aortic
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doi:10.1016/j.jvs.2007.08.012aneurysm (AAA) repair. Outcomes analysis is important for
hospital credentialing and surgeon selection, but it is criti-
cal for quality improvement, especially if it allows regional
benchmarking and comparison of processes of care that
define best practice. Unfortunately, the insular nature of
surgical practice makes it difficult to learn from other
surgeons.2 In this environment, it is difficult to compare
patient selection, decision making, and processes of care
that could have an important impact on clinical outcomes
and represent an opportunity for improvement. Further-
more, the infrequency of major complications, such as
stroke after CEA, makes it difficult for even high-volume
surgeons to recognize patterns of events that occur only
once every several years. How then can individual surgeons
improve their results, even if they carefully record them?
Fortunately, successful models for surgical outcome
improvement exist. In 1987, cardiac surgeons and re-
searchers from the five hospitals in Maine, New Hampshire,
and Vermont that performed coronary artery bypass graft-
ing (CABG) formed the Northern New England Cardio-
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prospectively collected data on CABG surgery and com-
pared risk-adjusted outcomes between centers. They iden-
tified variation in outcome related not to disease severity
but rather to different processes of care. By identifying
processes of care associated with CABG-related mortality,
the NNECDSG reduced regional operative mortality
by 24%.4
Stimulated by this success, a group of vascular surgeons
from Maine, New Hampshire, and Vermont formed the
Vascular Study Group of Northern New England
(VSGNNE) in 2002 with the following mission statement:
The VSGNNE is a voluntary, cooperative group of clini-
cians, hospital administrators and research personnel orga-
nized to improve the care of patients with vascular disease.
By collecting and exchanging information, the group strives
to continuously improve the quality, safety, effectiveness, and
cost of caring for patients with vascular disease.
The purpose of this report is to describe the results of
this activity during the first 4 years of data collection, from
2003 through 2006, in order to present a model for quality
assurance and improvement that might be adopted by
other regions.
METHODS
In 2001, 14 vascular surgeons from nine hospitals in
Maine, New Hampshire, and Vermont held four initial
meetings to develop a regional system to improve the
outcomes of patients with vascular disease. The group was
substantially assisted by Gerald T. O’Connor, principal
investigator of the NNECDSG. The above mission state-
ment was adopted, and a prospective registry was designed
to focus on CEA, infrainguinal lower extremity bypass
(LEB), and open and endovascular repair (EVAR) of infra-
renal AAAs. Variables for data collection were chosen that
represented key patient demographic variables, surgical
procedure details, and in-hospital outcomes, and a one-
page data entry form was devised for each operation. The
group also decided to collect follow-up data on key out-
comes 1 year after surgery.
Detailed definitions were developed for the approxi-
mately 100 variables on each form, including complica-
tions. Data forms and definitions are available online at the
VSGNNE Web site (http://www.vsgnne.org). Additional
surgeons have joined the group over time, such that 48
surgeons (Appendix, online only) have contributed patient,
procedural, and outcomes data from the nine hospitals
shown geographically in Fig 1. These comprise both aca-
demic and community hospitals with bed ranges of 25 to
615.
Data collection. Variables on the data forms were
grouped so that preoperative patient data could be col-
lected by nurses, research personnel, or surgeons; operative
details could be completed by surgeons or assistants; and
postoperative outcomes could be entered by nurses, re-
search personnel, or chart abstractors. The personnel used
for data collection varied by site according to resourceavailability. Uniformity of data collection was facilitated by
discussions at the biannual meetings and newsletters that
addressed questions concerning data entry. Individual
questions were also addressed by the central data collection
site. Completed forms were transmitted electronically or in
paper form to the central data collection site at Dartmouth-
Hitchcock Medical Center, where the project manager
(M. T. R.), consulting epidemiologist (D. S. L.), and
principal investigator (J. L. C.) are located.
Rigorous policies were developed to protect patient
confidentiality (available at http://www.vsgnne.org) to
comply with Health Insurance Portability and Accountabil-
ity (HIPAA) regulations. These VSGNNE policies in-
cluded de-identifying individual patients for all analyses and
data presentations while still allowing the procedural audit
with hospital administration data.
The study was approved by the institutional review
board (IRB) of each participating hospital. Initially, in-
formed consent was obtained from each patient, but this
requirement was later eliminated by the IRBs of eight of the
nine participating centers because the study was designed
primarily as a quality improvement and assurance initiative
and was deemed to be of no risk.
Pilot data collection began in selected centers in late
2002, but data in this report were collected from 48 par-
ticipating surgeons at nine participating hospitals from
January 2003 through December 2006. During the course
of the study, seven other surgeons from four other hospitals
began participating but later terminated their participation
owing to lack of interest or resources available to collect
data. All costs for data collection were borne by each center,
whereas central data collection and analysis was funded by
an initial grant (Grant No. 18-C-91674) from the Center
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Fig 1. Geographic location of participating centers in The Vascu-
lar Study Group of Northern New England.for Medicare and Medicaid Services (CMS).
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This is facilitated by the central site sending an electroni-
cally automated follow-up form for each operation to each
surgeon in advance of the expected 1-year office visit.
Follow-up data are reported here for operations through
February 2006 because later operations had not completed
1-year follow-up at the time this report was prepared. By
recording the date of key events such as death, stroke, and
amputation during the first year, event rates at key times
such as 30 days can be calculated as desired.
Review of outcomes and quality improvement.
Biannual meetings of the VSGNNE have been held each
year, with attendance by surgeons, data collection person-
nel, researchers, and hospital administrators. Because not
all participants can attend each meeting, minutes and slide
presentations are prepared after each meeting for debriefing
conferences held at each site. At each VSGNNE meeting,
data are presented for each surgeon and hospital, but with
the names blinded, so that each surgeon can compare his or
her data and the data of the hospital with the regional
average and also understand the regional variation.
During late 2003, VSGNNE members received in-
struction in continuous quality improvement techniques
and applied these principles to preoperative -blocker us-
age in 2004. A protocol was developed that recommended
starting -blocker therapy at least 2 weeks preoperatively
and continuing for at least 2 weeks postoperatively, with a
target usage of 90% to account for drug intolerance, con-
traindications, and that very low-risk patients likely do not
require -blockade. Data for each surgeon and each center
were displayed anonymously to demonstrate the variation
of usage. Each center shared its techniques for improving
-blocker usage, and each site was encouraged to locally
audit of 10 consecutive patients to assess -blocker usage
and make changes necessary to improve results. Data on
preoperative medication usage have since this time been
reported back to the participants at each VSGNNE meet-
ing. Preoperative medications were defined as those being
taken 36 hours before surgery.
Data validation. Submitted results from each center
were audited by comparison with hospital claims data to be
certain that all patients undergoing CEA, LEB, or AAA
repair had been entered by each participating surgeon. This
was done by extracting patients using International Classi-
fication of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) procedure codes who had been operated on
by a participating surgeon during the interval January 2003
though December 2005 (2006 data have not yet been
audited). Primary ICD-9 codes used for each procedure
were CEA, 38.12; LEB, 39.29; open AAA, 38.44, and
EVAR AAA, 39.71. As the result of an initial pilot study,
the following alternative procedure codes were added to
ensure complete capture of all patients: LEB, 38.48 (leg
aneurysm repair); open AAA, 39.25 (aortofemoral bypass),
and 38.46 (AAA resection).
Patients in the VSGNNE registry were then matched to
the administrative data using unique identifiers such as
Social Security Number. The inclusive nature of this searchled to more patients being identified in the administrative
data than should have been included in the VSGNNE
registry (eg, axillofemoral bypass under ICD-9 39.29),
which then required a record review at each site. The audit
also allowed validation of hospital deaths and discharge
status (ie, discharged home or elsewhere).
Statistical analysis. Data were entered into a Struc-
tured Query Language relational database and analyzed
using Stata 9.0 statistical software (StataCorp, College
Station, Tex). Data are reported for the overall regional
results, and the range of data among the nine centers is also
reported for selected variables. For centers who entered
data for 10 operations, their contribution to the range
reported in tables was censored owing to low accuracy of
the estimate. Categoric variables were compared with 2
analysis. Life-table methods were used to calculate time-
dependent results during follow-up.
RESULTS
From January 2003 through December 2006, 6143
operations were entered into the registry: CEA, 3097 (pri-
mary, 2984; redo, 62; combined CABG, 51); LEB, 1630
(occlusive disease, 1521; aneurysm disease, 109); open
AAA repair, 883 (elective, 667; symptomatic, 63; ruptured,
153); and EVAR, 533 (elective, 495; symptomatic, 22;
ruptured, 16). Patient preoperative demographic data are
summarized in Table I for the five major procedure subsets
of CEA, LEB occlusive disease, open elective, EVAR elec-
tive, and ruptured open AAA repair further described in this
report.
Carotid endarterectomy. The indication for primary
CEA was asymptomatic stenosis in 52%, ipsilateral cortical
or ocular symptoms in 37%, and contralateral, vertebrobasi-
lar or nonspecific symptoms in 11%. Preoperative imaging
included duplex scan in 96%, magnetic resonance angiog-
raphy (MRA) in 25%, computed tomography angiography
(CTA) in 17%, and arteriogram in 7%. Stenosis 80% was
present in 75% of operated patients.
CEA was performed by conventional (noneversion)
technique in 85% and with general anesthesia in 91%.
Among patients undergoing conventional CEA, 89% were
patched, most frequently with bovine pericardium (61%) or
polyester (23%). Electroencephalographic monitoring was
performed in 54%. Shunting was performed routinely in
37% and for a specific indication in an additional 6%. A
completion duplex scan was obtained in 34%.
Postoperative complications included re-exploration of
the artery after closure, 3%; cranial nerve injury, 6% (most
commonly the hypoglossal nerve); intravenous medication
for hypotension or hypertension, 27%; and ipsilateral neu-
rologic events, including transient ischemic attack, 0.4%,
minor stroke, 0.5%, and major stroke, 0.2%. Nonspecific
complications are listed for all operation types in Table II.
Lower extremity bypass. The indication for LEB for
occlusive disease was critical ischemia in 77% and claudica-
tion in 23%. Previous ipsilateral infrainguinal bypass had
been performed in 14% of patients, percutaneous translu-
minal angioplasty (PTA) or stenting in 7%, and minor
ovascu
isease
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formed in 81% of patients, duplex scanning in 40%, MRA in
10%, CTA in 8%, and vein mapping in 57%. General anes-
thesia was used in 71%. Graft origin was most frequently the
common femoral artery (69%), followed by the superficial
femoral artery (17%).
Graft recipient was above the above knee popliteal
artery in 27%, below knee popliteal in 31%, and infrapopli-
Table I. Patient demographic information
CEA (primary) LEB (occlusive)
No. of procedures 2984 1521
Mean age, y (range) 70 (38-97) 69 (26-96)
Female sex, % 40 33
White race, % 99 99
Smoking, %
Current 32 39
Ever 79 82
Comorbidities, %
Hypertension 86 86
Diabetes 30 55
Coronary artery disease 35 41
Previous CABG/PTCA 32 34
Congestive heart failure 8 19
COPD 24 31
Creatinine 1.8 mg/dL, % 6 17
Mean mg/dl 1.1 1.5
Cardiac stress test, %
Not done 60 62
Normal result 28 25
Abnormal result 12 14
Previous treatment, %
Arterial bypass 5 32
CEA 13 11
Aneurysm repair 3 3
PTA/stent 5 20
Major amputation 1 4
Pre-op medications, %
ASA 83 64
Clopidogrel 17 7
ASA or clopidogrel 86 66
-Blocker 83 79
Statin 67 54
CEA, Carotid endarterectomy; LEB, lower extremity bypass; EVAR, end
transluminal coronary angioplasty; COPD, chronic obstructive pulmonary d
Table II. Postoperative complications
Complication CEA (primary) LEB (occlusive
No. of patients 2984 1521
Myocardial infarction, % 0.8 4.7
New dysrhythmia, % 1.4 3.9
Congestive heart failure, % 0.7 3.8
Wound complication, % 0.1 4.1
Pulmonary, % NR 2.4
Worse renal function, % NR 5.2
Transfusion 2 U PRBC, % NR 6.2
Leg ischemia, % NA 5.6
Bowel ischemia, % NA NA
CEA, Carotid endarterectomy; LEB, lower extremity bypass; EVAR, endov
recorded.teal in 42% of cases. Vein grafts were used in 74%, polytet-rafluoroethylene (PTFE) grafts in 23%, and polyester grafts
in 3%, with 3% having a vein cuff. Vein grafts were used in
83% of patients with below knee bypass, and prosthetic
material was used in 61% of above knee bypass grafts.
Concomitant iliac bypass, PTA, or stenting was performed
in 10% of patients, and femoral endarterectomy was per-
formed in 23%. Minor amputation was performed in 11% of
patients, 5% required graft revision, and 2% underwent
pen AAA (elective) EVAR (elective) Rupture AAA (open)
667 495 153
71 (43-90) 74 (48-97) 73 (33-91)
26 19 14
99 100 100
43 31 45
92 87 90
81 80 82
15 19 17
35 41 38
31 31 28
7 14 11
39 40 44
9 7 16
1.2 1.2 1.3
21 58 96
59 28 1
20 15 3
3 3 1
7 6 8
2 3 3
3 3 2
1 0.4 1
69 65 50
6 6 2
70 67 51
83 75 65
58 60 31
lar repair; CABG, coronary artery bypass grafting, PTCA, percutaneous
; PTA, percutaneous transluminal angioplasty; ASA, acetylsalicylic acid.
pen AAA (elective) EVAR (elective) Rupture AAA (open)
667 495 153
7.8 2.4 26
14 3.4 19
4.7 1.0 16
3.3 1.0 18
12 2.6 53
12 3.2 29
9.7 0.8 40
2.3 0.9 8
3.5 0.5 15
r repair; PRBC, packed red blood cell units; NA, not applicable; NR, notO) O
asculasubsequent major amputation. At discharge, 90% of pa-
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and 98% had patent bypass grafts. Life-table graft patency
after discharge is shown in Fig 2.
Abdominal aortic aneurysm repair. Elective open
repair was performed at a mean AAA diameter of 6.1 cm
under general anesthesia alone in 30% and combined with
epidural anesthesia in 70%. Retroperitoneal exposure was
used in 25% and suprarenal clamping in 24% of cases.
Prosthetic grafts were 18 mm median diameter, 88% poly-
ester, 12% PTFE, with the distal anastomosis to the aorta in
52% of cases. Median blood loss was 1100 mL; 507 mL was
autotransfused; no packed red blood cells (PRBC) were
transfused, and 5 L of crystalloid was administered. Extu-
bation was in the operating room for 66% of patients, and
an additional 18% were extubated within 12 hours. Intra-
venous vasopressors were required by 31% of patients dur-
ing a median ICU stay of 2 days.
Elective EVAR was performed at a mean AAA diameter
of 5.7 cm under general anesthesia in 87% and regional
anesthesia in 13%. Thirty-one percent were judged unfit for
open repair. Graft manufacturer was Gore (Flagstaff, Ariz)
in 38%, Medtronic (Minneapolis, Minn) in 34%, and Cook
(Bloomington, Ind) in 24% of patients.
Median graft body and limb diameters were 26 and 15
mm. The internal iliac artery was covered unilaterally in
12% of cases and bilaterally in 2%. On completion, 2% of
patients had type I or III endoleak, and 26% had type II
endoleak. Conversion to open repair was required in 0.4%.
Median iodinated contrast used was 123 mL, blood
loss was 250 mL, crystalloid administered was 2.5 L, and
PRBC transfusion was 0 units. Postoperatively, 98% of
patients were extubated in the operating room, and 3%
required vasopressors during a median ICU stay of 0 days.
Open repair for a ruptured AAA was performed at a
mean aneurysm diameter of 7.5 cm. Retroperitoneal expo-
sure was used in 5% of patients and suprarenal clamping in
43%. Distal anastomosis was to the aorta in 63%. Median
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Fig 2. Life table-graft patency (%) after lower extremity bypass.blood loss was 3000 mL, with 1140 mL autotransfusion, 6U PRBC, and 7 L crystalloid. Only 4% of patients were
extubated in the operating room, and an additional 18%
were extubated 12 hours. Intravenous vasopressors were
required by 58% of patients during a median intensive care
unit stay of 4 days.
Key in-hospital outcomes for these procedure sub-
groups are summarized in Table III, including the overall
regional result and the range of outcomes among the nine
centers. Length of stay (LOS) from the date of operation to
discharge was significantly increased by the occurrence of
any of these postoperative complications (P  .001, Fig 3).
Preoperative medications. For all patients in the da-
tabase, preoperative -blocker usage increased from 72% in
the first half of 2003 to 91% in the second half of 2006 (P
 .001, Fig 4). The most pronounced increased occurred
during 2004, when a specific quality-improvement project
was initiated. This increase was due to -blockers specifi-
cally initiated preoperatively, which increased from 19% of
patients in the first half of 2003 to 34% in the second half of
2006 (P  .001) vs the percentage of patients receiving
Table III. In-hospital outcomes
Outcome Region results Center range
CEA (primary), No. 2984 65-993
Any stroke or death, % 1.0 0-2.5
Any complication, %* 4.1 1.4-5.8
Unplanned return to OR, % 1.9 0-3.7
Mean length of stay, d† 1.5 1.2-2.7
Not discharged home‡ 2.9 1.3-4.2
LEB (occlusive), No. 1521 51-634
Mortality, % 2.0 0.6-7.8
Major amputation, % 2.0 0-3.9
Any complication, %* 29 15-32
Unplanned return to OR, % 11.0 4-14
Mean length of stay, d† 6.9 3.7-9.6
Not discharged home, %‡ 26 7-51
Open AAA (elective), No. 667 13-148
Mortality, % 2.9 0-5.9
Any complication, %* 36 25-45
Unplanned return to OR, % 6 0-23
Mean length of stay, d† 10 8-13
Not discharged home, %‡ 17 8-20
EVAR (elective), No. 495 18-246
Mortality, % 0.4 0-2.4
Any complication, %* 11 7-30
Unplanned return to OR, % 1.4 0-3.7
Mean length of stay, d† 2.3 2.1-4.3
Not discharged home, %‡ 3 0-12
Rupture AAA (open), No. 153 10-53
Mortality 34 19-50
Any complication* 76 69-100
Unplanned return to OR, % 29 14-60
Mean length of stay, d† 15 11-20
Not discharged home‡ 51 29-58
CEA, Carotid endarterectomy; LEB, lower extremity bypass; EVAR, endo-
vascular repair; OR, operating room.
*Myocardial infarction, congestive heart failure, dysrhythmia, pulmonary,
renal, ischemia, infection, transfusion 2 U packed red blood cells.
†Length of stay from surgery date to discharge date.
‡Discharged to rehabilitation center or nursing home if admitted from
home.long-term -blocker therapy, which did not change signif-
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who initiated preoperative -blocker use in their patients
was initially 39% to 100% in the first 6 months of 2003.
Usage increased among all surgeons to 67% to 100% in the
last 6 months of 2006. From 2003 to 2006, the usage of
preoperative aspirin or clopidogrel increased from 73% to
83% and preoperative statin usage increased from 54% to
72% (both P  .001, Fig 4).
One-year follow-up data. Follow-up data were re-
ported for 83% of patients at a mean interval of 365 days
after operation. At the time of follow-up, 92% of patients
were alive and living at home, 2% lived in nursing homes,
and 6% had died since hospital discharge. Only 20% of
patients were currently smoking, compared with 36% pre-
operatively (P  .001). At follow-up, medications being
taken were aspirin in 81%, clopidogrel in 15%, -blockers in
64%, and statins in 68%. Of patients with LEB, 22% were
taking warfarin at follow-up. Key 1-year follow-up results
for the five operation subgroups are listed in Table IV.
Validation. The initial audit of administrative claims
data and the VSGNNE registry revealed 6182 unique
patients with potentially included operations and surgeons.
Initially, the computer directly matched 66% of these pa-
40%
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Beta-blockers
ASA-Clopidogrel
Statins
Fig 3. Preoperative medication usage among all patients. ASA,
Acetylsalicylic acid.
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Fig 4. Hospital length of stay from operation to discharge as a
function of any complication listed in Table III. CEA, Carotid
endarterectomy; LEB, lower extremity bypass; EVAR, endovascu-
lar repair.tients, and an additional 7% were matched by hand afterminor errors in data entry were corrected. Individual review
of the remaining 1672 patients determined that 13% had
operations that were not included in the registry that were
identified by broad ICD-9 codes (such as femorofemoral
bypass), 2% were errors based on incorrect ICD-9 coding,
5% had been done by nonparticipating surgeons, and 7%
were operations that should have been submitted to
VSGNNE. Data for these nonsubmitted 408 operations
were requested and have been received to date for 368.
This yielded complete data capture for 99% of procedures
that should have been entered into the VSGNNE database
by participating surgeons. Of these procedures, hospital
mortality was correctly entered into the VSGNNE database
for the 117 patients who died in-hospital. Discharge status
disagreement between administrative data and VSGNNE
data occurred in only 2.3% of discharges (home vs else-
where).
DISCUSSION
This work represents the results of a group of both
Table IV. One-year follow-up results
Result Region result Center range
CEA (primary), No. 1952 47-657
Mean follow-up, d 366 202-419
With follow-up, % 81 34-97
Persistent cranial nerve injury, % 1.0 0-1.6
Restenosis 70%, % 5.0 0-12
Reoperation or stent, %* 1.2 0-4.8
Ipsilateral stroke free, %* 98 95-100
Ipsilateral stroke-free survival, %* 95 85-96
LEB (occlusive), No. 1045 22-435
Mean follow-up, days 323 216-408
With follow-up, % 83 31-97
Ambulatory, % 91 73-96
Primary patency, %* 73 68-90
Primary-assisted patency, %* 79 68-85
Secondary patency, %* 81 72-86
Limb salvage, %* 83 76-100
Survival, %* 84 79-94
Open AAA (elective), No. 486 12-121
Mean follow-up, d 362 157-409
With follow-up, % 88 43-100
Reoperation, %* 3.3 1.7-8.3
Survival, %* 93 89-100
EVAR (elective), No. 320 27-173
Mean follow-up, days 369 364-373
With follow-up, % 84 38-100
Sac increase 5 mm, % 9 5-19
Endoleak, %
Type I or III 3.1 1.5-8.0
Type II 16 3-20
Reintervention, %* 4.0 0-8
Survival, %* 94 87-98
Rupture AAA (open), No. 108 17-32
Mean follow-up, d 374 328-469
With follow-up, % 89 60-100
Reoperation, %* 18 0-33
Survival, %* 48 44-58
CEA, Carotid endarterectomy; LEB, lower extremity bypass; EVAR, endo-
vascular repair.
*By life-table analysis at 1-year follow-up.academic and community vascular surgeons who are moti-
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We were strongly influenced by the successful model of
continuous quality improvement demonstrated by the
NNECDSG in many of our hospitals.2 Our initial surgical
results are comparable with single-center reports of out-
comes for CEA, LEB, and AAA repair and exceed the
results of some population-based reports.5-10 They do not
represent population-based results because not all hospitals
and surgeons in the region participate. By conducting an
audit of our procedure count and discharge status, how-
ever, our data represent an accurate accounting of the
outcomes of self-selected surgeons who are committed to
better understanding and improving their work.
The major accomplishment of the VSGNNE to date is
to demonstrate feasibility of a regional quality assurance
effort that has persisted for 4 years. This has provided
valuable information that is not normally available to indi-
vidual surgeons who, by nature, want to improve their
results. It has provided regional benchmarking data for
hospitals and surgeons with sufficient detail to allow anal-
ysis of variation in processes of care that could influence
outcome. The commitment to 1-year follow-up data
brought attention to missed follow-up visits, and in itself
provided a vehicle for improvement. The process fulfills
hospital needs for quality assurance programs required for
continued accreditation and will likely provide an appropri-
ate registry vehicle for surgeons to qualify for CMS pay-
ment incentive through the Physician Quality Reporting
Initiative.11
An early goal of the VSGNNE was to develop risk-
adjustment algorithms to compare observed and expected
outcomes at each center to identify variation due to pro-
cesses of care rather than different patient characteristics.3
Given the low frequency of major adverse events, it has
taken longer than expected to accrue sufficient numbers of
patients to conduct this analysis, although this remains our
long-term goal.
While waiting for future risk-adjusted analysis, we
chose to focus on process improvement, initially identifying
preoperative medication usage, and specifically -blockade,
as a target for improvement as a result of increasing evi-
dence for benefit of this therapy.12 In 2004, techniques to
implement preoperative -blockade were shared from each
center, and quality improvement principles were discussed
with the group by Eugene C. Nelson, a recognized quality
improvement expert. Although we cannot prove that the
observed improvement in -blocker usage from 72% in the
first 6 months of 2003 to 91% in the most recent 6 months
was a result of this method, the most rapid improvement
did correspond to the initial 6 months after our specific
quality improvement discussions.
It is possible that a Hawthorne effect of providing
feedback contributed to this improvement13 or that an
emphasis on this topic in the medical literature or other
hospital initiatives also encouraged the desired clinical be-
havior. Whatever the mechanism, the use of -blockade
now exceeds the 90% target threshold adopted by the
VSGNNE, and antiplatelet and statin usage has also in-creased substantially during this interval. Maintenance of
success and even further improvement appears significant,
especially since others have reported a loss of initial im-
provement in -blocker administration after completion of
an initially successful quality improvement project.14
Compared with claim-based registries, a substantial
advantage of the VSGNNE is the accurate recording of
clinical details that may allow an understanding of changes
necessary to improve outcome rather than simply reporting
outcome alone. As an example, LOS is tracked by most
hospitals as an important cost indicator. To safely shorten
LOS, however, one must identify the root causes of clinical
events—usually complications—that prolong LOS. In our
registry, we have identified the substantial and varying
impact of individual postoperative complications on LOS
for each procedure. Furthermore, we have identified sub-
stantial variation in the frequency of these complications
among the different centers and individual surgeons. Our
next effort will be to benchmark best practices by compar-
ative process analysis using site visits by participating sur-
geons to map the detailed processes of care performed by
surgeons at centers with excellent results. This technique
has been effectively used by the NNECDSG to reduce
mortality following CABG.15
In addition to the landmark achievements of the
NNECDSG, other successful registries have been developed.
The Department of Veterans Affairs National Surgical Quality
Improvement Program (NSQIP) is a model for providing
risk-adjusted outcomes based on prospectively collected pre-
operative patient characteristics.16 These investigators have
proven the superiority of this technique compared with the
use of administrative claims data for analyzing such outcomes.
They have pointed out the difficulty of using ICD-9 codes, as
we also have witnessed, because of their lack of specificity. This
is particularly important in vascular surgery, where many
ICD-9 procedure codes cover a broad range of markedly
different procedures.
The Society for Thoracic Surgeons National Cardiac Data
Base is an excellent example of a voluntary registry that that
provides nationally benchmarked, site-specific feedback and
an opportunity for quality improvement.17 This group dem-
onstrated a significant increase in preoperative -blocker us-
age in patients undergoing CABG at sites that received low-
intensity quality improvement interventions such as used by
the VSGNNE.17 These included identification of a local opin-
ion leader, providing benchmarking feedback, and techniques
for quality improvement.
Several statewide quality improvement efforts have also
demonstrated the value of confidential feedback of bench-
mark outcomes combined with meetings of participating
surgeons to discuss variation in care process and outcomes.
The Iowa Foundation for Medical Care demonstrated a
substantial reduction in stroke or death after CEA,18 and
the Alabama CABG Study Group demonstrated a signifi-
cant increase in internal mammary artery usage by using
these methods.19 Several vascular societies in Europe have
also formed registries that have provided useful data.20,21
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The Cleveland Vascular Society, The Eastern Vascular So-
ciety, The Kentucky Vascular Society, and The South Caro-
lina Vascular Surgical Society all formed database registries
for member participation.22-25After initial enthusiasm,
these were abandoned because of incomplete participation
and missing information from data forms. Among reasons
cited for failure was lack of perception of benefit by mem-
bers and difficulty completing complex data forms.22 In
this regard, we have learned the following lessons from our
experience in the VSGNNE:
● Biannual meetings of the group have promoted trust,
mutual respect, and a sense of a group commitment.
● Feedback of individual results with the anonymous
results of others has created peer pressure to improve
performance, such as -blocker usage.
● A confined geographic region has made travel to the
meetings feasible, even though participants have had
to donate their time to attend these day-long meet-
ings.
● Auditing the accuracy of our results using hospital
claims data was reassuring and important.
● Identifying a physician leader and a data coordinator at
each center has been critical. These individuals have
served as champions of the study at each site and
distribute results to participants who cannot attend a
biannual meeting.
● Providing minutes, newsletters, and slide sets has been
helpful to maintain member interest.
Finally, this effort requires significant resources. Cen-
tral data collection and analysis was funded by an external
grant, at an average cost of $100,000 per year. However,
each hospital and group practice has borne the additional
expense of data collection and data entry, which has re-
quired additional personnel, depending on the volume of
the center. Surgeons from several hospitals that did not
provide such assistance dropped out of the project after 1
year. This underscores the importance of involving not only
surgeons but also research personnel and administrators
from each center.
CONCLUSION
Our experience leads us to recommend this model of a
regional cooperative quality improvement group to others
who are interested in analyzing and improving their results.
This has allowed nine hospitals and 48 surgeons to compare
their outcomes with regional benchmarks for CEA, LEB,
and AAA repair and to initiate process improvement efforts.
The power of our registry increases with size, and momen-
tum is maintained by feedback of key results to individual
surgeons. We have begun the process of risk-adjustment to
understand and identify variations in processes of care that
could lead to future improvement. Relevant quality mea-
sures can now be accurately monitored, which not only
allows quality improvement but also helps surgeons and
hospitals prepare for pay-for-performance initiatives that
are being developed. We are confident that our methodol-ogy will meet the demands of public accountability and also
improve the quality of care for our patients.
We gratefully acknowledge Gerald T. O’Connor, DSc,
PhD, principal investigator of the Northern New England
Cardiovascular Disease Study Group, who provided invalu-
able assistance in starting this project; Eugene C. Nelson,
DSc, MPH, who provided quality-improvement consulta-
tion and instruction; and John H. Higgins, MS, who
designed the data input system. In addition, we gratefully
acknowledge the continued support of nurses, quality as-
surance staff, and research coordinators who collect data for
submission to the registry at each participating hospital.
Finally, we appreciate the initial support of two senior
vascular surgeons, Carl E. Bredenberg, MD, and David B.
Pilcher, MD, who were instrumental in developing this
project.
AUTHOR CONTRIBUTIONS
Conception and design: JC, DL, MR, JEJ, AS, BN
Analysis and interpretation: JC, DL, MR, JEJ, AS, BN
Data collection: JC, DL, MR, JEJ, AS, BN
Writing the article: JC
Critical revision of the article: DL, MR, JEJ, AS, BN
Final approval of the article: JC, DL, MR, JEJ, AS, BN
Statistical analysis: JC, DL, MR
Obtained funding: JC
Overall responsibility: JC
REFERENCES
1. Hertzer NR. Outcome assessment in vascular surgery—results mean
everything. J Vasc Surg 1995;21:6-15.
2. O’Connor GT, Plume SK, Wennberg JE. Regional organization for out-
comes research. Ann N Y Acad Sci 1993;703:44-50; discussion 50-1.
3. O’Connor GT, Plume SK, Olmstead EM, Coffin LH, Morton JR,
Maloney CT, et al. A regional prospective study of in-hospital mortality
associated with coronary artery bypass grafting. The Northern New
England Cardiovascular Disease Study Group. JAMA 1991;266:803-9.
4. O’Connor GT, Plume SK, Olmstead EM, Morton JR, Maloney CT,
Nugent WC, et al. A regional intervention to improve the hospital
mortality associated with coronary artery bypass graft surgery. The
Northern New England Cardiovascular Disease Study Group. JAMA
1996;275:841-6.
5. Killeen SD, Andrews EJ, Redmond HP, Fulton GJ. Provider volume
and outcomes for abdominal aortic aneurysm repair, carotid endarter-
ectomy, and lower extremity revascularization procedures. J Vasc Surg
2007;45:615-26.
6. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, et
al. Results of PREVENT III: a multicenter, randomized trial of edifo-
ligide for the prevention of vein graft failure in lower extremity bypass
surgery. J Vasc Surg 2006;43:742-751; discussion 751.
7. Dardik A, Lin JW, Gordon TA, Williams GM, Perler BA. Results of
elective abdominal aortic aneurysm repair in the 1990s: A population-
based analysis of 2335 cases. J Vasc Surg 1999;30:985-95.
8. Hallett JW Jr, Pietropaoli JA Jr, Ilstrup DM, Gayari MM, Williams JA,
Meyer FB. Comparison of North American Symptomatic Carotid End-
arterectomy Trial and population-based outcomes for carotid endarter-
ectomy. J Vasc Surg 1998;27:845-50; discussion 851.
9. Hertzer NR, Mascha EJ, Karafa MT, O’Hara PJ, Krajewski LP, Beven
EG. Open infrarenal abdominal aortic aneurysm repair: the Cleveland
Clinic experience from 1989 to 1998. J Vasc Surg 2002;35:1145-54.
10. Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, Harrington
DP. Patency results of percutaneous and surgical revascularization for
femoropopliteal arterial disease. Med Decis Making 1994;14:71-81.
JOURNAL OF VASCULAR SURGERY
Volume 46, Number 6 Cronenwett et al 110111. http://www.cms.hhs.gov/PQRI.
12. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blanken-
steijn JD, et al. The effect of bisoprolol on perioperative mortality and
myocardial infarction in high-risk patients undergoing vascular surgery.
Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo-
cardiography Study Group. N Engl J Med 1999;341:1789-94.
13. Lied TR, Kazandjian VA. A Hawthorne strategy: implications for
performance measurement and improvement. Clin Perform Qual
Health Care 1998;6:201-4.
14. Cantor MN, Lavarias V, Lam S, Mount L, Laskova V, Nakhamiyayev V,
et al. Barriers to implementing a surgical beta-blocker protocol. Jt
Comm J Qual Patient Saf 2005;31:640-8.
15. Kasper JF, Plume SK, O’Connor GT. A methodology for QI in the
coronary artery bypass grafting procedure involving comparative pro-
cess analysis. QRB Qual Rev Bull 1992;18:129-33.
16. Best WR, Khuri SF, Phelan M, Hur K, Henderson WG, Demakis JG, et
al. Identifying patient preoperative risk factors and postoperative ad-
verse events in administrative databases: results from the Department of
Veterans Affairs National Surgical Quality Improvement Program. J Am
Coll Surg 2002;194:257-66.
17. Ferguson TB Jr, Peterson ED, Coombs LP, Eiken MC, Carey ML,
Grover FL, et al. Use of continuous quality improvement to increase use
of process measures in patients undergoing coronary artery bypass graft
surgery: a randomized controlled trial. JAMA 2003;290:49-56.
18. Kresowik TF, Hemann RA, Grund SL, Hendel ME, Brenton M, Wiblin
RT, et al. Improving the outcomes of carotid endarterectomy: results of
a statewide quality improvement project. J Vasc Surg 2000;31:918-26.
begin our central processing of data were all critical in success.19. Holman WL, Allman RM, Sansom M, Peterson ED, Hubbard SG, Delong
JF, et al. Alabama coronary artery bypass grafting project: results of a
statewide quality improvement initiative. JAMA 2001;285:3003-10.
20. Kantonen I, Lepantalo M, Salenius JP, et al. Auditing a nationwide
vascular registry--the 4-year Finnvasc experience. Finnvasc Study
Group. Eur J Vasc Endovasc Surg 1997;14:468-74.
21. Bergqvist D, Troeng T, Einarsson E, Elfstrom J, Norgren L. Vascular
surgical audit during a 5-year period. Steering committee on behalf of the
Swedish Vascular Registry (Swedvasc). Eur J Vasc Surg 1994;8:472-7.
22. Taylor SM, Robison JG, Langan EM 3rd, Crane MM. The pitfalls of
establishing a statewide vascular registry: the South Carolina experi-
ence. Am Surg 1999;65:513-8; discussion 518-9.
23. Hertzer NR, Avellone JC, Farrell CJ, Plecha FR, Rhodes RS, Sharp WV,
et al. The risk of vascular surgery in a metropolitan community. With
observations on surgeon experience and hospital size. J Vasc Surg
1984;1:13-21.
24. Karmody AM, Blumenberg RM, Wall CA. Preliminary experience with
a large scale vascular registry. Am J Surg 1983;146:162-3.
25. Richardson JD, Main KA. Carotid endarterectomy in the elderly pop-
ulation: a statewide experience. J Vasc Surg 1989;9:65-73.
Submitted Jun 15, 2007; accepted Aug 19, 2007.
Additional material for this article may be found online
at www.jvascsurg.org.DISCUSSION
Dr Spence Taylor (Greenville, SC): Congratulations on a
wonderful presentation and also congratulations on an incredible
effort. This is a real nostalgic presentation for us. In South Caro-
lina, about 15 years ago, the state vascular society attempted this
and actually put 3 years of carotid endarterectomy data together,
accumulated over 1500 carotid endarterectomies, and we did it
almost identical to the way you did it. A lot of the processes that
you presented today were the same processes that we used.
There was a striking difference, however; yours worked, ours
failed. And it failed and lost momentum after about 3 years for
primarily two reasons. We had difficulty maintaining the financial
aspect of the registry, which was a major part, and then second, we
experienced a lack of perceived value, I believe, from the general
practicing private practice surgeon. Time and money, of course, is
a big issue with most practitioners, and I think at the end of the day
they lost the initiative to participate because of a lack of perception
of value.
Even when we, Jay Robison and I, put together the abstract
examining our experience and submitted it to the national and
regional vascular organizations, they did not accept the abstract.
We ended up presenting the data at the Southeastern Surgical
meeting and published it in the American Surgeon.
So, I think we may have been a victim of a different time. And
I think we clearly see what you are doing with this and it is a little
melancholy to see what we could have done. The process improve-
ment potential, as you have shown, may be the greatest part of this
initiative; but, unfortunately, we never got there. I congratulate
you on an outstanding manuscript and an outstanding effort.
Dr Jack L. Cronenwett: I appreciate your remarks. Why has
our registry worked and yours didn’t? There are many reasons why
this worked, but I’ll mention three. First, doing this regionally to
be able to meet together and develop trust was key. I think that
focusing on quality and providing members with feedback that
mattered was important. And I think, finally, getting buy-in from
hospitals that were familiar with this method based on the previous
work of the Northern New England Cardiovascular Disease Study
Group and also getting an initial grant from CMS to allow us toDr John Hallett (Charleston, SC): I have a couple of com-
ments and one question. The first comment is that this regional
quality improvement project would not have happened without Dr
Cronenwett’s leadership. Having been an original member of the
Study Group at Eastern Maine Medical Center, I saw so clearly the
importance of someone with vision and leadership.
Second, your hospital has to invest in a clinical coordinator
and data collector who helps your surgeons get the data recorded.
And finally and most important, Dr Cronenwett has emphasized
that everyone needs to convene twice a year to review the data and
select a few critical items for quality improvement.
My question: how can we take this type of regional quality
improvement model to a national level where others can use a
similar system and then, perhaps, benchmark with this wonderful
database that you have in New England?
Dr Cronenwett: As everyone knows, there are other regis-
tries. The STS has a registry that has been touted by CMS as being
the model for a demonstration project around pay for perfor-
mance. I met with people at CMS here in Baltimore during this
visit, and they believe that this database should qualify, starting in
January, for the physician quality reporting initiative.
There are other good databases like the NSQIP, which is
being rolled out nationally. The advantage of our database is that it
contains a large number of process-specific variables that we think
are going to be important going forward as we try to understand
not only what the results are but why are they different between
hospital A and B. What are the two hospitals doing differently?
Then, how can we make improvement?
So I do think that based on this, there may be an opportunity
for a future roll out of a national vascular database to share
benchmarking data but with regional administration to keep the
size manageable and I am looking into that.
Dr John Ricotta (Stony Brook, NY): I’d like to make a
comment. As maintenance of certification becomes important for
all of us, each of us is going to have to participate in some database
that monitors performance, either NSQIP or some other database,
and this clearly would qualify. My question relates to cost and
where the payment comes from. Many hospitals are already sup-
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hospitals involved in this type of specialty specific activity.
DrCronenwett: I think your comment about maintenance of
certification is important. And as you saw in one of the graphics, we
have hospitals from 25 beds to 600 beds. So you can imagine that
there are many different solutions in each hospital as to how data
are collected. These include surgeon entry of data—exclusively in
some hospitals—to research personnel to nurses on the floor.
Various hospitals have done it different ways. But by and large, the
larger hospitals have committed a part of an FTE to do this and
they have borne that cost.
Now, fortunately, we have had a grant from CMS to do the
central data processing. But I think each hospital has to commit to
local support for data collection. And the hook for that, the way to
attract them, is to start showing them results, to start showing
them how we’re making improvements in length of stay, and how
this process going forward can reduce costs.
Dr George Lavenson (Lahaina, Hawaii): Are there any plans
to include the outcomes from carotid artery stenting as well as
those of carotid endarterectomy? The reason that I ask is that it is
important to ensure that any stenting that is done has results that
are at least equivalent to very safely performed and available end-
arterectomy. In a three-step program for stroke prevention that we
are presenting tomorrow, consisting first of screening and then
diagnosis, the third step is a critical one of assuring that needed
intervention is done safely.
DrCronenwett:That is a good point. And one of the lessons we
have learned from this is don’t try to do too much too fast. But
recognizing where carotid stenting was, we actually began almost 2
years ago also collecting appropriate data on carotid stenting. I didn’t
present that today, but we now have almost 200 such patients in the
registry and we hope to be bringing that forward at another time.Dr Anil Hingorani (Brooklyn, NY): In one of your slides,
there was a 25% incidence of morbidity and mortality on limb loss
and amputations in one of the surgeons who is doing lower
extremity bypasses. How did you get those types of surgeons to
participate and volunteer these data? I don’t see how you would be
able to do that.
DrCronenwett:Well, one of the things that we learned when
we first started presenting these results in a small group setting is
that the surgeons are very interested in improving their results.
Most of them don’t know the details about their results. And when
someone sees a result like that, the response is: “Gee, I see a lot of
people have outstanding results, I want to know how you’re
getting those.”
That’s been our experience. And I think it is because the
surgeons who are doing this are doing it voluntarily, they are
committed to improving, based on their participation, and our
sense is that a surgeon with what appears to be poor outcome is
motivated to do better.
Dr Giovanni Ferrante (Hingham, MA): It sounds like you
have got great buy-in from the surgeons who participated and from
the institutions. But there are at least two other groups at each
institution that may be doing some of these procedures. There
should be motivation on the part of the institutions to include the
interventional radiologists and the cardiologists. Is there any
movement in that direction?
Dr Cronenwett: We have invited anyone who is doing these
procedures to participate. And since we started recording carotid
stent procedures, for example, we now have some cardiologists
who are participating in that phase of the registry. We have a couple
neurosurgeons who are participating around carotid endarterec-
tomy. So yes, we have done that.
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Concord Hospital, Concord, New Hampshire
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Fletcher Allen Health Care, Burlington, VT
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Walter Keller, DO
